Reported 8 months ago
The release of data for the weight loss and diabetes drug tirzepatide by Eli Lilly & Co. resulted in a selloff of stocks for companies involved in sleep-related disorders like ResMed Inc., Inspire Medical Systems Inc., and AdaptHealth Corp. The data showed promising results in reducing the severity of obstructive sleep apnea in obese patients, impacting the market and leading to concerns among healthcare device manufacturers about the potential effects of weight-loss drugs on related conditions like obesity. Analysts from Citigroup Inc. and Truist Securities expressed concerns and downgraded ratings for certain companies in the wake of the data release.
Source: YAHOO